Envestnet Asset Management Inc. Has $280.16 Million Stake in Boston Scientific Corporation $BSX

Envestnet Asset Management Inc. grew its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 2.3% in the third quarter, HoldingsChannel.com reports. The fund owned 2,869,555 shares of the medical equipment provider’s stock after acquiring an additional 64,643 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Boston Scientific were worth $280,155,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Norges Bank acquired a new position in Boston Scientific in the second quarter valued at approximately $2,089,937,000. Edgewood Management LLC acquired a new position in shares of Boston Scientific during the 2nd quarter valued at $746,655,000. Parnassus Investments LLC boosted its stake in Boston Scientific by 42,978.9% during the third quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider’s stock worth $672,128,000 after acquiring an additional 6,868,459 shares in the last quarter. Bessemer Group Inc. boosted its stake in Boston Scientific by 14,391.8% during the second quarter. Bessemer Group Inc. now owns 2,919,801 shares of the medical equipment provider’s stock worth $313,618,000 after acquiring an additional 2,899,653 shares in the last quarter. Finally, Jennison Associates LLC grew its holdings in Boston Scientific by 133.5% in the third quarter. Jennison Associates LLC now owns 4,938,746 shares of the medical equipment provider’s stock worth $482,170,000 after purchasing an additional 2,823,744 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q4 beat on both EPS and revenue; revenue grew ~15.9% year-over-year, and margins improved — the underlying quarter was strong, showing continued organic growth across several franchises. Boston Scientific announces results for fourth quarter and full year 2025
• Neutral Sentiment: Analyst coverage and the company’s earnings materials/earnings call provide detail for valuation and segment trends — useful for investors who want to dig into segment-level drivers and management’s assumptions. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Management’s FY‑2026 guidance was modestly below or roughly in line with Street expectations (FY EPS range and revenue range came in light enough to reset growth assumptions), and Q1 guidance was cautious — that outlook is the main driver of the selloff. Boston Scientific shares slide on cautious 2026 revenue forecast
• Negative Sentiment: Electrophysiology (one of Boston Scientific’s higher-growth, higher-profile segments) underperformed vs. expectations, which worried investors about near-term growth momentum in a key franchise. Boston Scientific hits an 18-month low on a ‘sore spot’ for its most hyped device
• Negative Sentiment: Unusually large put-option activity and heavy trading signaled short-term bearish positioning and hedging, amplifying downside pressure. BSX Earnings: Boston Scientific Stock Plunges on Weak Guidance
• Negative Sentiment: CEO insider selling (large block disclosed) adds to near-term negative sentiment even though insider transactions can be for many reasons. Insider sale SEC filing

Analyst Ratings Changes

Several equities analysts have recently weighed in on BSX shares. TD Cowen reiterated a “buy” rating on shares of Boston Scientific in a report on Monday. Evercore ISI set a $112.00 price target on Boston Scientific in a research note on Monday, January 5th. Needham & Company LLC reiterated a “buy” rating on shares of Boston Scientific in a report on Thursday, January 15th. The Goldman Sachs Group restated a “buy” rating and set a $112.00 price objective on shares of Boston Scientific in a report on Friday, January 9th. Finally, Truist Financial cut their target price on Boston Scientific from $130.00 to $120.00 and set a “buy” rating on the stock in a report on Thursday, December 18th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $121.84.

Insider Transactions at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the transaction, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,396,580. This represents a 42.32% decrease in their position. The SEC filing for this sale provides additional information. 0.50% of the stock is owned by company insiders.

Boston Scientific Stock Down 17.6%

BSX stock opened at $75.50 on Thursday. The firm has a market capitalization of $111.92 billion, a PE ratio of 40.37, a P/E/G ratio of 1.63 and a beta of 0.67. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. Boston Scientific Corporation has a twelve month low of $75.00 and a twelve month high of $109.50. The stock’s 50 day moving average is $94.37 and its 200-day moving average is $99.13.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The business had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same period in the prior year, the firm posted $0.70 EPS. Boston Scientific’s quarterly revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Sell-side analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.